A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma

Key Points

• The trial aims to evaluate the clinical activity and proof-of-mechanism of tobemstomig in melanoma patients who have previously experienced checkpoint inhibitors.
• Conducted as a phase 1 clinical trial
• Included patients with CPI-experienced melanoma
• Assessed safety and tolerability across various advanced solid tumors
• Evaluated antitumor activity and pharmacodynamic responses
• Demonstrated a tolerable and manageable safety profile
• Showed encouraging antitumor activity in patients
• Provided proof-of-mechanism indicating therapeutic potential of tobemstomig

Abstract